COR · Cencora, Inc.
$322.03
+0.80 (+0.25%)
At close · Aug 28
Market Cap
$61.58B
Shares
190.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$322.03
Open$322.30
Day$320.39–323.74
52W close$252.74–374.75
Avg vol 30d1.3M
Short int4.6M · 2.4% float · 2.4d
Short vol38%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 10 wks
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−0%
below
Price vs 50-day avg
+5%
above
RSI (14)
56
neutral
MACD trend
Negative
52-week position
57%
mid-range
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−11%
trailing
YTD return
−5%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $307 › 200d $323 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +106 funds added
Insider flow
Distributing
Net -$2.4M over 90 days · 33% sells
Short interest
Falling
2.43% of float · ▼ -10.1% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,343 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+9%
Y/Y
Gross margin
4%
expanding
EPS growth
+6%
Y/Y
Free cash flow
$3.2B
Buyback
$1.9B
remaining
Balance sheet
$1.3B
net debt
Quant / Vol
risk profile
Volatility
31%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Adjusted diluted earnings per share
· Fiscal 2026
Non-GAAP
Initiated
$17.75 – $17.95
U.S. Healthcare Solutions Segment
· Fiscal 2026
Non-GAAP
Initiated
14.5% – 15.5%
Adjusted operating income
· Fiscal 2026
Non-GAAP
Raised
13% – 14%
May 6, 2026
12% – 14%
changed to
Aug 5, 2026
13% – 14%
Other
· Fiscal 2026
Non-GAAP
Initiated
6%
Adjusted effective tax rate
· Fiscal 2026
Non-GAAP
Maintained
20%
May 6, 2026
20%
changed to
Aug 5, 2026
20%
Prior guidance
period ended
· from the 8-K filed Aug 6, 2025
Revenue growth
· fiscal year 2025
9%
U.S. Healthcare Solutions segment revenue growth
· fiscal year 2025
9% – 10%
International Healthcare Solutions segment revenue growth
· fiscal year 2025
6% – 7%
U.S. Healthcare Solutions segment operating income growth
· fiscal year 2025
20% – 21%
Adjusted effective tax rate
· fiscal year 2025
20.5% – 21%
Guided vs delivered
· last 1 settled
EPS contribution from exclusive COVID-19 product distribution
fiscal year '24, mostly occurring in the first quarter
guided $0.02 – $0.10
$7.53
Beat +12450.0%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−0%
Neutral
Price vs 50-day avg
+5%
Bullish
RSI (14)
56
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $307 › 200d $323 — 200d above 50d
Institutional flow
Distributing
-7% holders QoQ · +106 funds added
Insider flow
Distributing
Net -$2.4M over 90 days · 33% sells
Short interest
Falling
2.43% of float · ▼ -10.1% MoM · 2.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,343 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $253
Now $322 · 57%
Range high $375
vs 200-day avg 0%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted free cash flows non-GAAP | $1.14B | the nine months ended June 30, 2026 | — |
| Free cash flows | $1.18B | the nine months ended June 30, 2026 | — |
| International Healthcare Solutions revenue | $7.68B | FY2026 Q3 | +5.9% |
|
|
|||
| International Healthcare Solutions segment operating income | $165.85M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Other segment operating income | $108.74M | Three months ended June 30, 2026 filing | — |
| Total segment operating income | $1.24B | Three months ended June 30, 2026 filing | — |
| U.S. Healthcare Solutions revenue | $74.86B | FY2026 Q3 | +4.9% |
|
|
|||
| U.S. Healthcare Solutions segment operating income | $966.18M | Three months ended June 30, 2026 filing | — |
|
|
|||
| Adjusted Operating income non-GAAP | $1.26B | three months ended March 31, 2026 | — |
| Adjusted Operating income (constant currency, Consolidated) non-GAAP | $1.26B | three months ended March 31, 2026 | — |
| Adjusted Operating income (International Healthcare Solutions segment, as reported) non-GAAP | $176M | three months ended March 31, 2026 | — |
| Adjusted Operating income (International Healthcare Solutions segment, constant currency) non-GAAP | $175M | three months ended March 31, 2026 | — |
| International Healthcare Solutions revenue growth on a constant currency basis non-GAAP | 6.2% | first quarter of fiscal 2026 | — |
| International Healthcare Solutions segment operating income decrease on a constant currency basi non-GAAP | 17% | first quarter of fiscal 2026 | — |
| Other operating income | $91.4M | first quarter of fiscal 2026 | — |
| Other revenue | $2.1B | first quarter of fiscal 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COR
this stock
Cencora, Inc.
|
$61.58B | -4.7% | +9.3% | 24.0 | 2.4% |
|
MCK
Mckesson Corp
|
$103.82B | +8.9% | +3.1% | 23.9 | 2.1% |
|
CAH
Cardinal Health Inc
|
$54.55B | +14.1% | +14.2% | — | 2.7% |
|
HSIC
Henry Schein Inc
|
$10.06B | +18.4% | +5.9% | 26.3 | 6.2% |
|
EBOSY
EBOS Group Limited/ADR
|
$2.69B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COR | +1.3% | +3.4% | -11.0% | +3.4% | -4.7% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.8% | +0.4% | -24.4% | +0.4% | -17.5% |
Capital returns
Latest dividend
$0.60
/ share · ex Aug 14, 2026
Paid (TTM)
$2.40
/ share · 4 payouts
Dividend yield (TTM, derived)
0.75%
Buyback program
· as of Jun 30, 2026
Authorized
$2.00B
Spent (derived)
$117.80M
Remaining
$1.88B
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1140859
CUSIP
03073E105
13F (30d)
914 filings
888 filers
Visit website
Investor relations